John Kuruvilla
Impact in
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment
- Oncology top 0.5%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lymphoma Diagnosis and Treatment 176
- Genetics 78
- Chronic Lymphocytic Leukemia Research 60
- Co-authors
- Michael CrumpPier Luigi ZinzaniPhilippe ArmandArmand KeatingMargaret A. ShippHans A. MessnerVikas GuptaJeffrey H. Lipton
- Journals
- Blood (84 papers)Biology of Blood and Marrow Transplantation (23 papers)Journal of Clinical Oncology (21 papers)Bone Marrow Transplantation (21 papers)Hematological Oncology (13 papers)
- Partner nations
- CanadaUnited StatesItaly
In The Last Decade
John Kuruvilla
275 papers receiving 7.0k citations
Hit Papers
Peers
Comparison fields: 5 of 112
- Pathology and Forensic Medicine 3.8k
- Oncology 4.4k
- Genetics 1.5k
- Hematology 1.3k
- Immunology 1.4k
Countries citing papers authored by John Kuruvilla
This map shows the geographic impact of John Kuruvilla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Kuruvilla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Kuruvilla more than expected).
Fields of papers citing papers by John Kuruvilla
This network shows the impact of papers produced by John Kuruvilla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Kuruvilla. The network helps show where John Kuruvilla may publish in the future.
Co-authors
The 25 scholars most cited alongside John Kuruvilla, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 0 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 0 | |
| 9 | 2022 | 3 | |
| 10 | 2021 | 10 | |
| 11 | 2020 | 2 | |
| 12 | 2019 | 30 | |
| 13 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Hit paper breakdown → | 2018 | 455 |
| 14 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Hit paper breakdown → | 2017 | 1042 |
| 15 | 2017 | 112 | |
| 16 | 2017 | 110 | |
| 17 | 2015 | 28 | |
| 18 | 2014 | 75 | |
| 19 | 2010 | 80 | |
| 20 | 2009 | 414 |
About John Kuruvilla
John Kuruvilla is a scholar working on Pathology and Forensic Medicine, Genetics, Hematology, Oncology and Neurology, having authored 295 papers that have together received 7.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (176 papers), CAR-T cell therapy research (74 papers), Chronic Lymphocytic Leukemia Research (60 papers), Hematopoietic Stem Cell Transplantation (47 papers), Viral-associated cancers and disorders (41 papers), CNS Lymphoma Diagnosis and Treatment (32 papers), Acute Myeloid Leukemia Research (27 papers) and Cancer Immunotherapy and Biomarkers (24 papers). The work is most often cited by research in Pathology and Forensic Medicine (3.8k citations), Oncology (4.4k citations), Genetics (1.5k citations), Hematology (1.3k citations) and Immunology (1.4k citations). John Kuruvilla has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Michael Crump, Pier Luigi Zinzani, Philippe Armand, Armand Keating, Margaret A. Shipp, Hans A. Messner, Vikas Gupta, Jeffrey H. Lipton, Craig H. Moskowitz and Jean‐Marie Michot. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Bone Marrow Transplantation and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.